BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/3/2021 7:34:23 AM | Browse: 572 | Download: 788
 |
Received |
|
2021-07-20 21:14 |
|
Peer-Review Started |
|
2021-07-20 21:18 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-08-06 18:04 |
|
Revised |
|
2021-08-10 01:23 |
|
Second Decision |
|
2021-11-22 03:33 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-11-25 01:24 |
|
Articles in Press |
|
2021-11-25 01:24 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-11-30 23:45 |
|
Publish the Manuscript Online |
|
2021-12-03 07:34 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Diagnostic biomarkers for pancreatic cancer: An update
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ming Yang and Chun-Ye Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ming Yang, DVM, PhD, Postdoctoral Fellow, Department of Surgery, University of Missouri, One Hospital Dr., Medical Science Building, Room M272, Columbia, MO 65212, United States. yangmin@health.missouri.edu |
| Key Words |
Pancreatic ductal adenocarcinoma; Diagnosis; Biomarkers; Panel; Clinical trials |
| Core Tip |
The development of ideal diagnostic biomarkers for pancreatic cancer (PC) is critically important for early diagnosis, large-scale screening, monitoring of therapeutic response, prediction of risk, and prognosis. So far, the only approved serum marker for PC diagnosis is carbohydrate antigen 19-9 (CA 19-9) in the United States; although, many potential biomarkers have been investigated. However, CA 19-9 has low sensitivity; hence, new solutions are needed. Herein, we summarize some of the ongoing clinical trials that aim to investigate the application of biomarkers in PC diagnosis. |
| Publish Date |
2021-12-03 07:34 |
| Citation |
Yang M, Zhang CY. Diagnostic biomarkers for pancreatic cancer: An update. World J Gastroenterol 2021; 27(45): 7862-7865 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i45/7862.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i45.7862 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
